Seattle Genetics Inc SGEN:NASDAQ

Last Price$71.11NASDAQ Closing Price as of 4:00PM ET 9/16/19

Today's Change+0.48(0.68%)
Bid (Size)$71.08 (14)
Ask (Size)$71.11 (5)
Day Low / High$68.74 - 71.75
Volume456.2 K

View Biotechnology IndustryPeer Comparison as of 09/16/2019


Seattle Genetics Inc ( NASDAQ )

Price: $71.11
Change: +0.48 (0.68%)
Volume: 456.2 K
4:00PM ET 9/16/2019

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $74.21
Change: +1.56 (2.15%)
Volume: 1.0 M
4:00PM ET 9/16/2019

Neurocrine Biosciences Inc ( NASDAQ )

Price: $97.80
Change: +1.39 (1.44%)
Volume: 520.2 K
4:00PM ET 9/16/2019

Exact Sciences Corp ( NASDAQ )

Price: $104.41
Change: -2.30 (2.16%)
Volume: 1.3 M
4:00PM ET 9/16/2019

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $84.77
Change: +1.08 (1.29%)
Volume: 554.0 K
4:00PM ET 9/16/2019

Read more news Recent News

Seattle Genetics, Astellas Get FDA Priority Review for Enfortumab Vedotin for Bladder Cancer - SGEN Firm
12:56PM ET 9/16/2019 MT Newswires

Seattle Genetics (SGEN) and Astellas Pharma said on Monday the US Food and Drug Administration (FDA) has accepted the Biologics License Application for...

Analyst Actions: Oppenheimer Raises Seattle Genetics to Outperform From Perform, Price Target to $82 From $77
7:46AM ET 9/12/2019 MT Newswires

Seattle Genetics' (SGEN) average rating among analysts is a buy, with an average price target of $86. Price: 70.85, Change: +2.20, Percent Change: +3.20...

Significant Insider Sales Reported in Shares of Seattle Genetics (SGEN) Extending the Trend of Last Quarter
10:17PM ET 9/03/2019 MT Newswires

Four insiders -- Dr Siegall, Simpson, Liu, and Dr Himes -- today, sold 47,709 shares of Seattle Genetics having a market value of approximately $3,492,998,...

Seattle Genetics (SGEN) Insiders Make Significant Share Sales Extending the Trend of Last Quarter
10:17PM ET 9/02/2019 MT Newswires

There was substantial level of selling of Seattle Genetics shares by insiders today, as disclosed in form 4 documents filed with the SEC. Four insiders --...

Company Profile

Business DescriptionSeattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. View company web site for more details
Address21823 30th Drive SE
Bothell, Washington 98021
Number of Employees1,302
Recent SEC Filing09/10/20194
Chairman, President & Chief Executive OfficerClay B. Siegall
Chief Financial & Accounting OfficerTodd E. Simpson
Chief Technical OfficerVaughn B. Himes
Senior Vice President-Clinical DevelopmentRobert J. Lechleider

Company Highlights

Price Open$69.37
Previous Close$70.63
52 Week Range$50.71 - 84.37
Market Capitalization$11.5 B
Shares Outstanding161.7 M
SectorHealth Technology
Next Earnings Announcement10/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.40
Beta vs. S&P 500N/A
Revenue$654.7 M
Net Profit Margin-36.94%
Return on Equity-21.43%

Analyst Ratings as of 09/11/2019

Consensus RecommendationConsensus Icon
Powered by Factset